High content toxicology

Because drug toxicity is typically a combination of multiple mechanisms, investigating a single toxicological marker is unlikely to be sufficiently predictive of cellular toxicity. High Content Screening simultaneously analyses multiple indicators of cellular toxicity using fluorescent imaging techniques, providing improved toxicity predictions relative to single end-point assays.

Contact us to learn more about how Cyprotex can help you identify toxicity.

Cyprotex offer two tiers of High Content Toxicology;

Cytotoxicity Screening Panel

• Investigates four parameters:
• Mitochondrial membrane potential
• Cytochrome c release
• Nuclear size and intensity
• Cell number

• Identifies common mechanism of toxicity such as:
• Necrosis
• Apoptosis
• Mitochondrial toxicity

• Greater sensitivity than single end-point assays

• Typically performed at an early stage during drug discovery

Contact us to learn more about our cytotoxicity screening panel.

CellCiphr™ Toxicity Profiling

• Investigates three panels of cell types
• Cytotoxicity - using HepG2 cells
• Hepatotoxicity - using primary rat hepatocytes
• Cardiotoxicity - using H9c2 cardiomyocytes

• Assesses a panel of up to 10 key toxicity markers for each panel

• Evaluates a 10-point dose-response curve in duplicate at 3 time points to assess early- and late-stage toxic response markers.

• Ranks and classifies unknown compounds against known toxic effects using Cyprotex’s proprietary database of in vitro and in vivo toxicity data.

• Typically performed from late discovery to early preclinical development

Contact us to learn more about CellCiphr™ High Content Toxicology profiling.